JP2022532851A - ホットフラッシュの非ホルモン治療 - Google Patents
ホットフラッシュの非ホルモン治療 Download PDFInfo
- Publication number
- JP2022532851A JP2022532851A JP2021563312A JP2021563312A JP2022532851A JP 2022532851 A JP2022532851 A JP 2022532851A JP 2021563312 A JP2021563312 A JP 2021563312A JP 2021563312 A JP2021563312 A JP 2021563312A JP 2022532851 A JP2022532851 A JP 2022532851A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hot flashes
- administration
- dopamine
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010060800 Hot flush Diseases 0.000 title claims abstract description 129
- 208000033830 Hot Flashes Diseases 0.000 title claims abstract description 123
- 238000011282 treatment Methods 0.000 title claims abstract description 52
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims abstract description 25
- 239000000556 agonist Substances 0.000 claims abstract description 24
- 102000015554 Dopamine receptor Human genes 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 35
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 34
- 229960001879 ropinirole Drugs 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 32
- 229960000488 tizanidine Drugs 0.000 claims description 24
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 claims description 24
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims description 9
- 229960002870 gabapentin Drugs 0.000 claims description 9
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 8
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 8
- 229960002896 clonidine Drugs 0.000 claims description 8
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 7
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 7
- 229960002296 paroxetine Drugs 0.000 claims description 7
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 7
- 229960003089 pramipexole Drugs 0.000 claims description 7
- 229960004688 venlafaxine Drugs 0.000 claims description 7
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 7
- 108050004812 Dopamine receptor Proteins 0.000 claims description 6
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 6
- 229960001233 pregabalin Drugs 0.000 claims description 6
- 229960003179 rotigotine Drugs 0.000 claims description 4
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 4
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 claims description 3
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims 8
- 238000001990 intravenous administration Methods 0.000 claims 3
- -1 pyribezil Chemical compound 0.000 claims 1
- 102000005962 receptors Human genes 0.000 abstract description 42
- 108020003175 receptors Proteins 0.000 abstract description 42
- 101150049660 DRD2 gene Proteins 0.000 abstract description 30
- 239000000833 heterodimer Substances 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 14
- 229940052760 dopamine agonists Drugs 0.000 abstract description 8
- 230000003054 hormonal effect Effects 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 230000037361 pathway Effects 0.000 abstract description 7
- 230000032683 aging Effects 0.000 abstract description 6
- 239000000048 adrenergic agonist Substances 0.000 abstract description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 4
- 229960003638 dopamine Drugs 0.000 abstract description 2
- 238000011477 surgical intervention Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 44
- 230000001457 vasomotor Effects 0.000 description 23
- 229940088597 hormone Drugs 0.000 description 14
- 239000005556 hormone Substances 0.000 description 14
- 238000002657 hormone replacement therapy Methods 0.000 description 14
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 12
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 12
- 208000008454 Hyperhidrosis Diseases 0.000 description 12
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
- 229940028334 follicle stimulating hormone Drugs 0.000 description 12
- 102000009151 Luteinizing Hormone Human genes 0.000 description 11
- 108010073521 Luteinizing Hormone Proteins 0.000 description 11
- 229940011871 estrogen Drugs 0.000 description 11
- 239000000262 estrogen Substances 0.000 description 11
- 229940040129 luteinizing hormone Drugs 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000003446 ligand Substances 0.000 description 10
- 230000009245 menopause Effects 0.000 description 10
- 230000035900 sweating Effects 0.000 description 10
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 9
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 9
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 9
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 9
- 238000001794 hormone therapy Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 206010027304 Menopausal symptoms Diseases 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 229960003604 testosterone Drugs 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000037007 arousal Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000000517 effect on sleep Effects 0.000 description 5
- 238000011010 flushing procedure Methods 0.000 description 5
- 210000003016 hypothalamus Anatomy 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010051055 Deep vein thrombosis Diseases 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000009098 adjuvant therapy Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 229960001076 chlorpromazine Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960003878 haloperidol Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000008906 neuronal response Effects 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 208000006155 precocious puberty Diseases 0.000 description 2
- 210000005215 presynaptic neuron Anatomy 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960001150 ramelteon Drugs 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 229940107444 ropinirole 4 mg Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000004799 sedative–hypnotic effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960003188 temazepam Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 206010000125 Abnormal dreams Diseases 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000008238 LHRH Receptors Human genes 0.000 description 1
- 108010021290 LHRH Receptors Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 1
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000004185 hypothalamic-pituitary-gonadal axis Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940025679 tizanidine 4 mg Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960004010 zaleplon Drugs 0.000 description 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本出願は、2012年3月5日に出願された米国特許出願第13/411,660号、2014年4月4日に出願された米国特許出願第14/245,509号、2017年3月2日に出願された米国特許出願第15/447,675号、及び2019年4月22日に出願された米国特許出願第16/390,276号の一部継続出願であり、それらの優先権を主張する。これらの先の出願は、参照により本明細書に組み込まれる。
女性の閉経期症状を治療するとき、D2受容体ファミリー活性を有する種々の分子(D2、D3、又はD4ドーパミン作動薬)は、とりわけアルファ2アドレナリン作動薬と組み合わされるとき、ホットフラッシュを含む閉経期症状を非常によく制御することが、臨床研究によって明らかに示されている。ロピニロール(D2受容体ファミリードーパミン作動薬)とチザニジン(アルファ2アドレナリン作動薬)を用いて4人の女性を治療することにより、これらの女性の症例研究を行った。D2作動薬単独でのホットフラッシュの治療の有効性が、本研究を通して実証された。ホットフラッシュの軽減は、アルファ2アドレナリン作動薬を用いた追加治療を通じて、さらに増強された。この組合せにより、長期にわたる臨床的ベネフィットが得られた。
Claims (12)
- ホットフラッシュの治療方法であって、
前記方法は、
D2、D3又はD4ドーパミン受容体に結合することができるドーパミン作動薬である化学組成物の有効量をホットフラッシュを経験している人に投与するステップと、
前記組成物の投与の効果を評価するステップとを含む、方法。 - 前記化学組成物の投与の方法は、錠剤中での前記組成物の投与、液体形態での前記組成物の経口投与、液体形態での前記組成物の静脈内投与、経皮パッチを使用する前記組成物の投与、及び、吸入による前記組成物の投与からなる群から選択される、請求項1に記載のホットフラッシュの治療方法。
- ホットフラッシュの治療方法であって、
前記方法は、
D2、D3又はD4ドーパミン受容体に結合することができるドーパミン作動薬である化学組成物の有効量をホットフラッシュを経験している人に投与するステップと、
アルファ2アドレナリン受容体に結合することができるアルファ2アドレナリン作動薬である化学組成物の有効量を前記人に投与するステップと、
前記の両組成物の投与の効果を評価するステップとを含む、方法。 - ドーパミン作動薬である前記化学組成物の投与の方法は、錠剤中での前記組成物の投与、液体形態での前記組成物の経口投与、液体形態での前記組成物の静脈内投与、経皮パッチを使用する前記組成物の投与、及び、吸入による前記組成物の投与からなる群から選択され、並びに、
アルファ2アドレナリン作動薬である前記化学組成物の投与の方法は、錠剤中での前記組成物の投与、液体形態での前記組成物の経口投与、液体形態での前記組成物の静脈内投与、経皮パッチを使用する前記組成物の投与、及び、吸入による前記組成物の投与からなる群から選択される、請求項3に記載のホットフラッシュの治療方法。 - ホットフラッシュの治療のための組成物であって、
D2、D3又はD4ドーパミン受容体に結合することができるドーパミン作動薬である物質と、
アルファ2アドレナリン作動薬である物質とを含む、組成物。 - 錠剤として個体に投与することができる形態を構成する、請求項5に記載の組成物。
- 前記組成物は、錠剤として個体に投与することができる形態を構成し、
前記ドーパミン作動薬及び前記アルファ2アドレナリン作動薬は、前記錠剤内に別々に配置される、請求項6に記載の組成物。 - 前記組成物は、錠剤として個体に投与することができる形態を構成し、
前記ドーパミン作動薬及び前記アルファ2アドレナリン作動薬は、前記錠剤内に組み合わせられる、請求項6に記載の組成物。 - 液体として個体に経口投与することができる形態を構成する、請求項5に記載の組成物。
- 液体として個体に静脈内投与することができる形態を構成する、請求項5に記載の組成物。
- 吸入により個体に投与することができる形態を構成する、請求項5に記載の組成物。
- D2、D3又はD4ドーパミン受容体に結合することができるドーパミン作動薬である前記物質は、ロピニロール、ロチゴチン、プラミペキソール、ピリベジル、ベンラファキシン、パロキセチン、ガバペンチン、及び、プレガバリンからなる群より選択され、並びに、
アルファ2アドレナリン作動薬である前記物質は、チザニジン及びクロニジンからなる群より選択される、請求項5に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/390,276 US11903926B1 (en) | 2012-03-05 | 2019-04-22 | Non-hormonal treatment of hot flashes |
US16/390,276 | 2019-04-22 | ||
PCT/US2020/027238 WO2020219270A1 (en) | 2019-04-22 | 2020-04-08 | Non-hormonal treatment of hot flashes |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022532851A true JP2022532851A (ja) | 2022-07-20 |
Family
ID=72940665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021563312A Pending JP2022532851A (ja) | 2019-04-22 | 2020-04-08 | ホットフラッシュの非ホルモン治療 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3958862A4 (ja) |
JP (1) | JP2022532851A (ja) |
KR (1) | KR20220010721A (ja) |
AU (1) | AU2020262851A1 (ja) |
BR (1) | BR112021021260A2 (ja) |
CA (1) | CA3137710A1 (ja) |
IL (1) | IL287457A (ja) |
SG (1) | SG11202112822VA (ja) |
WO (1) | WO2020219270A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9468631B1 (en) * | 2012-03-05 | 2016-10-18 | Robert L. Knobler | Method and compound for treatment of menopausal symptoms |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2378918C (en) * | 1999-07-22 | 2007-01-23 | University Of Rochester | Method of treating symptoms of hormonal variation, including hot flashes |
AU2005215376B2 (en) * | 2004-02-18 | 2011-01-20 | Sunovion Pharmaceuticals Inc. | Dopamine-agonist combination therapy with sedatives for improving sleep quality |
US8420624B2 (en) * | 2007-12-04 | 2013-04-16 | Yung Shin Pharm. Ind. Co., Ltd. | Methods for treating or preventing symptoms of hormonal variations |
ES2574210T3 (es) * | 2010-03-02 | 2016-06-15 | Fervent Pharmaceuticals, Llc | Métodos y composiciones para tratar o prevenir los síntomas de las variaciones hormonales |
-
2020
- 2020-04-08 JP JP2021563312A patent/JP2022532851A/ja active Pending
- 2020-04-08 AU AU2020262851A patent/AU2020262851A1/en active Pending
- 2020-04-08 WO PCT/US2020/027238 patent/WO2020219270A1/en unknown
- 2020-04-08 KR KR1020217037881A patent/KR20220010721A/ko unknown
- 2020-04-08 CA CA3137710A patent/CA3137710A1/en active Pending
- 2020-04-08 EP EP20795747.3A patent/EP3958862A4/en active Pending
- 2020-04-08 BR BR112021021260A patent/BR112021021260A2/pt unknown
- 2020-04-08 SG SG11202112822VA patent/SG11202112822VA/en unknown
-
2021
- 2021-10-21 IL IL287457A patent/IL287457A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9468631B1 (en) * | 2012-03-05 | 2016-10-18 | Robert L. Knobler | Method and compound for treatment of menopausal symptoms |
Also Published As
Publication number | Publication date |
---|---|
SG11202112822VA (en) | 2021-12-30 |
WO2020219270A1 (en) | 2020-10-29 |
BR112021021260A2 (pt) | 2022-02-08 |
CA3137710A1 (en) | 2020-10-29 |
EP3958862A4 (en) | 2023-01-25 |
AU2020262851A1 (en) | 2021-11-18 |
KR20220010721A (ko) | 2022-01-26 |
IL287457A (en) | 2021-12-01 |
EP3958862A1 (en) | 2022-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI330083B (en) | Methods for treating or preventing symptoms of hormonal variations | |
Chegini et al. | Review of evidence for the use of steroids in orthognathic surgery | |
Pareja et al. | SUNCT syndrome: diagnosis and treatment | |
Spetz et al. | Incidence and management of hot flashes in prostate cancer | |
US6165504A (en) | Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients | |
US10806722B1 (en) | Method and compound for treatment of menopausal symptoms | |
Adelson et al. | Treatment of hot flushes in breast and prostate cancer | |
JP2022532851A (ja) | ホットフラッシュの非ホルモン治療 | |
US11903926B1 (en) | Non-hormonal treatment of hot flashes | |
Okeke et al. | An overview of menopause associated vasomotor symptoms and options available in its management | |
Penarrocha et al. | Cluster headache and cocaine use | |
Campbell | Facial pain due to migraine and cluster headache | |
JP7265551B2 (ja) | 血管運動症状を治療または予防するための組成物および方法 | |
US9693993B1 (en) | Method for treatment of menopausal symptoms | |
Khainju | The efficacy and tolerability of SNRI (Venlafaxine And Desvenlafaxine) for the treatment of vasomotor symptoms in menopausal women | |
Yang et al. | Case study: management of post-parotidectomy neuropathic pain with Sativex | |
Klasser et al. | Trigeminal autonomic cephalalgias. Part 3: short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing | |
CN113677348A (zh) | 偏头痛的治疗 | |
Harsono | Seizure threshold, hormones and anti epileptic drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220310 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220310 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230322 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230921 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231219 |